
LAVA Therapeutics NV
NASDAQ:LVTX

LAVA Therapeutics NV
Cash from Investing Activities
LAVA Therapeutics NV
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
Cash from Investing Activities
-$17.6m
|
CAGR 3-Years
-228%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Pharming Group NV
AEX:PHARM
|
Cash from Investing Activities
$31.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cash from Investing Activities
-€4.1m
|
CAGR 3-Years
-112%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-13%
|
|
![]() |
Uniqure NV
NASDAQ:QURE
|
Cash from Investing Activities
$163m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
argenx SE
XBRU:ARGX
|
Cash from Investing Activities
-$732.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
![]() |
Merus NV
NASDAQ:MRUS
|
Cash from Investing Activities
-$220.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
What is LAVA Therapeutics NV's Cash from Investing Activities?
Cash from Investing Activities
-17.6m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Cash from Investing Activities amounts to -17.6m USD.
What is LAVA Therapeutics NV's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-228%
The average annual Cash from Investing Activities growth rates for LAVA Therapeutics NV have been -228% over the past three years .